(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(0.12%) $82.73
(1.13%) $2.05
(-0.47%) $2 346.60
(-0.92%) $27.41
(-0.24%) $959.20
(-0.19%) $0.933
(-0.30%) $10.99
(-0.53%) $0.796
(1.56%) $93.31
@ $6.86
Utstedt: 14 feb 2024 @ 21:49
Avkastning: -29.15%
Forrige signal: feb 14 - 15:30
Forrige signal:
Avkastning: 2.01 %
Live Chart Being Loaded With Signals
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence...
Stats | |
---|---|
Dagens volum | 1.27M |
Gjennomsnittsvolum | 727 290 |
Markedsverdi | 582.90M |
EPS | $0 ( 2024-03-14 ) |
Neste inntjeningsdato | ( $-0.470 ) 2024-05-09 |
Last Dividend | $0.800 ( 2019-09-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.23 |
ATR14 | $0.00900 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Marrazzo Jeffrey D | Buy | 250 000 | Stock Option (right to buy) |
2024-02-20 | Gv 2023 Gp, L.l.c. | Buy | 0 | Common Stock |
2024-02-25 | Gottesdiener Keith Michael | Buy | 100 000 | Stock Option (right to buy) |
2024-02-21 | Brudnick Richard | Buy | 135 747 | Stock Option (right to buy) |
2024-02-21 | Duffield Jeremy | Buy | 180 995 | Stock Option (right to buy) |
INSIDER POWER |
---|
34.78 |
Last 97 transactions |
Buy: 38 299 882 | Sell: 27 394 093 |
Volum Korrelasjon
First Trust Heitman Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
First Trust Heitman Korrelasjon - Valuta/Råvare
First Trust Heitman Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-4.65M (0.00 %) |
EPS: | $-2.18 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-4.65M (0.00 %) |
EPS: | $-2.18 |
FY | 2022 |
Omsetning: | $5.21M |
Bruttogevinst: | $-6.80M (-130.60 %) |
EPS: | $-1.250 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.55 |
Financial Reports:
No articles found.
First Trust Heitman Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0900 | 2015-12-23 |
Last Dividend | $0.800 | 2019-09-10 |
Next Dividend | $0 | N/A |
Payout Date | 2019-09-12 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | $3.83 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.65 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.022 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.937 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.53 | 0.800 | 2.33 | 1.864 | [1 - 3] |
quickRatioTTM | 2.16 | 0.800 | 2.02 | 1.617 | [0.8 - 2.5] |
cashRatioTTM | 0.737 | 1.500 | 7.02 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0703 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 440.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.699 | 2.00 | -0.566 | -1.132 | [0 - 30] |
freeCashFlowPerShareTTM | -1.788 | 2.00 | -0.894 | -1.788 | [0 - 20] |
debtEquityRatioTTM | 0.102 | -1.500 | 9.59 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -12.13 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.156 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.17 | 1.000 | -0.321 | 0 | [1 - 100] |
returnOnEquityTTM | -0.937 | 2.50 | -7.41 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.788 | 2.00 | -0.596 | -1.788 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.699 | 2.00 | -0.566 | -1.132 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0624 | 1.500 | -2.92 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.952 |
First Trust Heitman
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.